AHA Scientific Sessions Daily News 2

6 2018 SCIENTIFIC SESSIONS DAILY NEWS SUNDAY | NOV. 11, 2018 P rimary results from the REDUCE-IT study found that supplemental icos- apent ethyl, a prescription medication approved to reduce triglycerides ≥ 500 mg/dL, significantly reduced the risk of important cardiovascular events by 25 percent. This includes a 31 percent reduction in myocardial infarction, a 28 percent reduction in stroke and a 20 percent reduc- tion in death due to cardiovascular causes in statin-treated men and women with hypertriglycemia. “We hope REDUCE-IT will transform the care of millions of patients worldwide,” said Deepak L. Bhatt, MD, MPH, of Brigham and Women’s Hospital in Boston, who presented the findings Saturday. REDUCE-IT randomized more than 8,000 patients with well-controlled LDL-cholesterol on statins for secondary or primary REDUCE-IT finds medication added to statins reduces risks among patients with high triglycerides “That side effect might have worried me, but we saw a 28 percent reduction in stroke, which is the worst thing that AFib could do. I wouldn’t not use icosapent ethyl in a REDUCE-IT population because of the risk of AFib.” – Deepak Bhatt, MD, MPH see REDUCE-IT , page 16 Deepak L. Bhatt, MD, MPH SCIENCE & TECHNOLOGY HALL OPENS facebook.com/ ahameetings JOIN THE CONVERSATION @AHAmeetings @AHAScience youtube.com/ user/AHASessions #AHA18 youtube.com/user/ AHAScienceNews

RkJQdWJsaXNoZXIy MjI2NjI=